RESEARCHER PROFILE
Professor Kristofer Thurecht, Deputy Director of Research & Senior
Group leader, Australian Institute for Bioengineering and Nanotechnology,
University of Queensland, Australia
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
Professor Thurecht undertook his PhD at the University of Queensland and decided he wanted to go to the University of Nottingham in the UK, where his mentors pushed him into the new field of nanomedicine. On returning to Australia he brought his ideas on nanomedicine back to the University of Queensland, where he works today.
His research focuses on understanding how nanomedicines behave in biological environments using high-end imaging infrastructure, with a focus on radiopharmaceutical research to establish next generation drugs for diseases like cancer.
Nanomedicine research, particularly in the field of cancer treatment, has the potential to revolutionise traditional medicine and improve the quality of life for those suffering from the disease. Radiopharmaceuticals and molecular imaging are revolutionising cancer treatment by providing targeted therapies and precise drug delivery, showing potential for groundbreaking advancements in the field.
Radiopharmaceuticals utilise radiation as a potent therapy for treating diseases, particularly cancer. As Professor Thurecht states, the development of radiopharmaceutical for cancer treatment is a promising and innovative field in nanomedicine.
Outside of research Professor Thurecht enjoys fishing and boating with family on weekends.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Clinical Research in Emergency Medicine
Professor Daniel Fatovich is a senior emergency physician and clinical researcher at Royal Perth Hospital Emergency Department (ED), with over 30 years’ experience in the design and conduct of clinical research in Emergency Medicine. He is also Head of the Centre for Clinical Research in Emergency Medicine (CCREM) within the Harry Perkins Institute of Medical Research.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
